Long‐term therapy of chronic delta hepatitis with peginterferon alfa - Heller, T.; Rotman, Y.; Koh, C.; Clark, S.; Haynes‐Williams, V.; Chang, R.; McBurney, R.; Schmid, P.; Albrecht, J.; Kleiner, D. E.; Ghany, M. G.; Liang, T. J.; et al. (Alimentary pharmacology & therapeutics, 2014)
Keywords: Adolescent; Adult; Aged; Angiogenesis Inhibitors - therapeutic use; Antiviral Agents - administration & dosage; Antiviral Agents - adverse effects; Antiviral Agents - therapeutic use; Biological and medical sciences; Disease Progression; Dose-Response Relationship, Drug; Female; Hepatitis B Surface Antigens - blood; Hepatitis D virus; Hepatitis D, Chronic - complications; Hepatitis D, Chronic - drug therapy; Human viral diseases; Humans; Infectious diseases; Interferon-alpha - administration & dosage; Interferon-alpha - adverse effects; Interferon-alpha - therapeutic use; Liver Cirrhosis - etiology; Liver Cirrhosis - virology; Male; Medical sciences; Middle Aged; Polyethylene Glycols - administration & dosage; Polyethylene Glycols - adverse effects; Polyethylene Glycols - therapeutic use; Prospective Studies; Recombinant Proteins - administration & dosage; Recombinant Proteins - adverse effects; Recombinant Proteins - therapeutic use; Time Factors; Treatment Outcome; Viral diseases; Viral hepatitis; Young Adult; Infection; Chronic; Treatment; Viral disease; Viral hepatitis delta; Cytokine; Digestive diseases; Hepatic disease; Interferon; Pegylated form; Long term